文献速递肿瘤 PET/CT神经核医学

68Ga-Satoreotide Trizoxetan在胃肠胰神经内分泌肿瘤中的最佳给药方案:随机析因II期研究

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2021-07-02

该前瞻性随机2×3析因多中心II期研究评估了68Ga-satoreotide trizoxetan在转移性胃肠胰神经内分泌肿瘤患者中的最佳肽质量和放射性活度范围。结论:100-200 MBq放射性活度联合不超过50 µg肽质量为未来III期研究的最佳给药方案。

要点

  • 68Ga-satoreotide trizoxetan PET/CT检出NET病灶数至少为增强CT的两倍。
  • 不同肽质量范围及放射性活度范围间病灶检出数无差异。
  • 推荐未来III期研究采用100-200 MBq放射性活度、肽质量≤50 µg。

核心结论

  • 100-200 MBq放射性活度联合不超过50 µg肽质量被确认为68Ga-satoreotide trizoxetan未来III期研究的最佳给药方案。

研究设计与样本

  • 患者第1天接受肽质量5-20 µg,第16-22天接受30-45 µg,各联合3种68Ga放射性活度范围(40-80、100-140或160-200 MBq)之一。
  • 注射后50-70分钟行全身PET/CT显像,主要终点为相对增强CT的NET病灶检出率。

主要发现

  • 在6种肽质量与放射性活度范围组合中,68Ga-satoreotide trizoxetan PET/CT或PET单独检出的中位病灶数至少为增强CT的两倍。
  • 2种肽质量范围之间或3种放射性活度范围之间,检出的病灶数无差异。
  • 40-80 MBq范围在肝脏中观察到相对病灶计数较低的趋势。
  • 每患者体重放射性活度(MBq/kg)与检出病灶数之间未观察到关系。
  • 基于每患者病灶数的中位诊断灵敏度在不同肽质量与放射性活度范围间为85%至87%。

关键数值与推荐

  • 最佳给药方案推荐:放射性活度100-200 MBq,肽质量不超过50 µg。
  • 中位诊断灵敏度范围85%-87%(基于每患者病灶数,各肽质量与放射性活度范围)。

临床怎么用

  • 未来III期研究可采用100-200 MBq放射性活度联合不超过50 µg肽质量的给药方案。
  • 68Ga-satoreotide trizoxetan PET/CT在NET病灶检出方面显著优于增强CT。

局限性

  • 40-80 MBq范围在肝脏中相对病灶计数较低仅为趋势,未确立统计学差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumor (NET) detection and localization. However, the optimal peptide mass and radioactivity ranges for 68Ga-satoreotide trizoxetan have not yet been established. We therefore aimed to determine its optimal dosing regimen in patients with metastatic gastroenteropancreatic NETs in a prospective, randomized, 2 × 3 factorial, multicenter phase II study. Methods: Patients received 68Ga-satoreotide trizoxetan at a peptide mass of 5-20 µg on day 1 of the study and of 30-45 µg on days 16-22, at 1 of 3 68Ga radioactivity ranges (40-80, 100-140, or 160-200 MBq). Whole-body PET/CT imaging was performed 50-70 min after each injection. The primary endpoint was the detection rate of NET lesions imaged by 68Ga-satoreotide trizoxetan relative to contrast-enhanced CT (for each of the 6 peptide mass and radioactivity range combinations). Results: Twenty-four patients were evaluated in the per-protocol analysis. The median number of lesions detected by 68Ga-satoreotide trizoxetan PET/CT or PET alone was at least twice as high as the number detected by contrast-enhanced CT across the 6 studied peptide mass and radioactivity range combinations. There were no differences between the 2 peptide mass ranges or between the 3 radioactivity ranges in the number of identified lesions. However, a trend toward a lower relative lesion count was noted in the liver for the 40- to 80-MBq range. No relationship was observed between the radioactivity range per patient's body weight (MBq/kg) and the number of lesions detected by 68Ga-satoreotide trizoxetan. The median diagnostic sensitivity of 68Ga-satoreotide trizoxetan PET/CT, based on the number of lesions per patient, ranged from 85% to 87% across the different peptide mass and radioactivity ranges. Almost all reported adverse events were mild and self-limiting. Conclusion: A radioactivity of 100-200 MBq with a peptide mass of up to 50 µg was confirmed as the optimal dosing regimen for 68Ga-satoreotide trizoxetan to be used in future phase III studies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Virgolini I, Bahri S, Kjaer A, et al. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2021. PMID: 34215673. doi:10.2967/jnumed.121.261936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。